NMTR · 9 Meters Biopharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | ($64.0K) |
| R&D | $31.01M | $22.00M | $10.93M | $13.72M | $7.56M | $190.0K |
| SG&A | $11.01M | $9.66M | $10.52M | $10.57M | $10.66M | $4.98M |
| Total Operating Expenses | $42.02M | $36.76M | $60.88M | $25.55M | $18.22M | $8.89M |
| D&A | $8.5K | $7.6K | $18.5K | $21.6K | $5.8K | - |
| Operating Income | ($42.02M) | ($36.76M) | ($60.88M) | $25.55M | $18.22M | ($8.95M) |
| Interest Expense | $2.67M | $47.2K | $4.05M | $1.83M | $6.15M | $93.0K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($43.77M) | ($36.78M) | ($61.50M) | ($27.05M) | ($24.16M) | ($7.92M) |
| EPS - Basic | ($3.38) | ($0.58) | - | - | - | - |
| EPS - Diluted | ($3.38) | ($0.58) | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.65M | $46.99M | $37.85M | $4.59M | $5.73M | $426.0K |
| Accounts Receivable | - | - | - | - | - | $90.0K |
| Inventory | - | - | - | - | - | $101.0K |
| Accounts Payable | $5.05M | $2.43M | $1.49M | $3.89M | $3.62M | $441.0K |
| Current Assets | $33.02M | $49.99M | $38.93M | $5.22M | $6.41M | $663.0K |
| Total Assets | $33.15M | $50.17M | $39.16M | $5.30M | $6.45M | $677.0K |
| Current Liabilities | $30.70M | $8.46M | $6.85M | $14.91M | $10.11M | $2.65M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $30.75M | $8.57M | $7.02M | - | - | - |
| Stockholders' Equity | $2.40M | $41.60M | $32.14M | ($9.61M) | ($3.66M) | ($1.97M) |
| Retained Earnings | ($212.61M) | ($168.84M) | ($132.06M) | ($70.56M) | ($43.52M) | ($40.01M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($37.24M) | ($29.48M) | ($19.41M) | ($17.97M) | ($15.17M) | ($8.43M) |
| Investing Cash Flow | ($2.8K) | ($2.43M) | ($3.19M) | ($11.9K) | ($38.7K) | - |
| Financing Cash Flow | $19.91M | $41.05M | $55.86M | $16.84M | $20.56M | $9.76M |
| CapEx | $2.8K | $12.5K | $2.5K | $11.9K | $38.7K | - |
| Free Cash Flow | ($37.25M) | ($29.49M) | ($19.41M) | ($17.98M) | ($15.21M) | - |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.85 | 0.80 | 0.32 | 0.66 | 0.63 | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -132.0% | -73.3% | -157.0% | -510.7% | -374.4% | -1170.6% |
| Return on equity | -1823.2% | -88.4% | -191.3% | 281.3% | 660.3% | 401.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.08 | 5.91 | 5.68 | 0.35 | 0.63 | 0.25 |
| Quick ratio | 1.08 | 5.91 | 5.68 | 0.35 | 0.63 | 0.21 |
| Cash ratio | 0.41 | 5.56 | 5.53 | 0.31 | 0.57 | 0.16 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -15.8x | -779.1x | -15.0x | 14.0x | 3.0x | -96.3x |
| Equity multiplier | 13.81 | 1.21 | 1.22 | -0.55 | -1.76 | -0.34 |
| Liabilities / Assets | 0.93 | 0.17 | 0.18 | - | - | - |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -14.3% | 39.6% | - | 40.2% | - | -50.6% |
| Net income growth (YoY) | -19.0% | 40.2% | -127.4% | -11.9% | -204.9% | -27.6% |
| EPS growth (YoY) | -482.8% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -26.3% | -51.9% | -8.0% | -18.2% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -94.2% | 29.4% | - | -162.7% | -85.5% | 60.4% |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing 9 METERS BIOPHARMA against the 5 most active filers in the same SIC group.